Business ❯ Pharmaceuticals ❯ Biotechnology

Drug Development

Obesity Treatments Clinical Trials Acquisitions Molecular Glue Degraders Clinical Research Prostate Cancer Therapeutics Cancer Treatment CAR T-cell Therapy Cystic Fibrosis Treatments Oral Biologics

3 ARTICLES

last mo.

Alnylam and Inceptive Agree Up to $2 Billion Partnership to Use AI for siRNA Drug Design

The deal will combine Inceptive’s generative foundation models with Alnylam’s decades of siRNA data to speed selection of preclinical candidates using modelled targets and predicted chemical modifications.

7 ARTICLES

2mo ago

Pfizer and Innovent Strike Up to $10.5 Billion Oncology Collaboration

6 ARTICLES

3mo ago

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

9 ARTICLES

4mo ago

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

10 ARTICLES

5mo ago

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

3 ARTICLES

5mo ago

Viking Therapeutics' Obesity Drug Moves Into Phase 3 as Investors Weigh Upside

4 ARTICLES

6mo ago

Lilly, Repertoire Strike Up-to-$1.93 Billion Autoimmune Drug Pact

3 ARTICLES

6mo ago

Insilico, Qilu Strike Near-$120 Million AI Drug Discovery Pact for Cardiometabolic Therapies

7 ARTICLES

6mo ago

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

3 ARTICLES

6mo ago

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

7 ARTICLES

7mo ago

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

6 ARTICLES

8mo ago

Telix Securities Suit Advances as Investor Firms Push Lead-Plaintiff Bids Before Jan. 9 Deadline

3 ARTICLES

8mo ago

Vertex Tops Q3 Estimates on CF Franchise as New Drugs Miss and Outlook Edges Higher

4 ARTICLES

9mo ago

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

4 ARTICLES

9mo ago

Rani Therapeutics and Chugai Sign Oral Biologics Collaboration Worth Up to $1.085 Billion

9 ARTICLES

9mo ago

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

4 ARTICLES

9mo ago

Takeda and Nabla Bio Expand AI Protein-Design Deal With Potential Payouts Above $1 Billion

7 ARTICLES

10mo ago

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet

5 ARTICLES

10mo ago

CSL Secures VarmX Acquisition Option, Funding Phase 3 of Factor Xa Reversal Drug

3 ARTICLES

11mo ago

Novo Nordisk Strikes Exclusive srRNA Pact With Replicate in Deal Worth Up to $550 Million

Drug Development

Alnylam and Inceptive Agree Up to $2 Billion Partnership to Use AI for siRNA Drug Design

Pfizer and Innovent Strike Up to $10.5 Billion Oncology Collaboration

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

Viking Therapeutics' Obesity Drug Moves Into Phase 3 as Investors Weigh Upside

Lilly, Repertoire Strike Up-to-$1.93 Billion Autoimmune Drug Pact

Insilico, Qilu Strike Near-$120 Million AI Drug Discovery Pact for Cardiometabolic Therapies

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

Never miss stories about

Drug Development

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

Telix Securities Suit Advances as Investor Firms Push Lead-Plaintiff Bids Before Jan. 9 Deadline

Vertex Tops Q3 Estimates on CF Franchise as New Drugs Miss and Outlook Edges Higher

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

Rani Therapeutics and Chugai Sign Oral Biologics Collaboration Worth Up to $1.085 Billion

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Takeda and Nabla Bio Expand AI Protein-Design Deal With Potential Payouts Above $1 Billion

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet

CSL Secures VarmX Acquisition Option, Funding Phase 3 of Factor Xa Reversal Drug

Novo Nordisk Strikes Exclusive srRNA Pact With Replicate in Deal Worth Up to $550 Million

Never miss stories about

Drug Development